Geode Capital Management LLC Buys 83,068 Shares of Personalis, Inc. (NASDAQ:PSNL)

Geode Capital Management LLC raised its stake in Personalis, Inc. (NASDAQ:PSNL) by 20.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 498,470 shares of the company’s stock after acquiring an additional 83,068 shares during the period. Geode Capital Management LLC owned approximately 0.94% of Personalis worth $2,683,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of PSNL. nVerses Capital LLC bought a new position in shares of Personalis in the third quarter worth $40,000. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its holdings in Personalis by 42.5% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock valued at $81,000 after buying an additional 4,504 shares during the period. International Assets Investment Management LLC lifted its holdings in shares of Personalis by 438.0% during the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock worth $113,000 after acquiring an additional 17,082 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Personalis during the 3rd quarter worth approximately $210,000. Finally, Barclays PLC increased its stake in Personalis by 45.4% in the third quarter. Barclays PLC now owns 65,468 shares of the company’s stock valued at $352,000 after acquiring an additional 20,444 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors.

Personalis Stock Performance

NASDAQ PSNL opened at $5.98 on Wednesday. The firm’s fifty day moving average price is $4.68 and its two-hundred day moving average price is $4.31. The stock has a market cap of $422.48 million, a PE ratio of -3.56 and a beta of 1.75. Personalis, Inc. has a fifty-two week low of $1.12 and a fifty-two week high of $7.20.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). The firm had revenue of $25.71 million for the quarter, compared to the consensus estimate of $20.67 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. During the same quarter in the prior year, the firm earned ($0.51) EPS. As a group, sell-side analysts predict that Personalis, Inc. will post -1.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on PSNL shares. HC Wainwright raised their target price on Personalis from $9.00 to $11.00 and gave the company a “buy” rating in a report on Friday, December 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $7.25 price objective on shares of Personalis in a research note on Friday, December 20th.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.